Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua C Doloff

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Nature Biomedical Engineering|December 13, 2021
Less fibrosis around softer silicone implantsStuart J Bauer, Joshua C Doloff
Nature Materials|March 27, 2021
MAP-ing a way towards tissue repairJessica L Stelzel, Joshua C Doloff
Cancer Research|January 13, 2012
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regressionJoshua C Doloff, David J Waxman
Anti-Cancer Agents in Medicinal Chemistry|July 23, 2013
Adenoviral vectors for prodrug activation-based gene therapy for cancerJoshua C Doloff, David J Waxman
BMC Cancer|May 9, 2015
Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenograftsJoshua C Doloff, David J Waxman
BMC Cancer|September 15, 2010
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+Joshua C Doloff, Ting Su, David J Waxman
Human Gene Therapy|September 6, 2008
Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletionsJoshua C Doloff, David J Waxman, Youssef Jounaidi
Current Cancer Drug Targets|May 17, 2007
Conditionally replicating adenoviruses for cancer treatmentYoussef Jounaidi, Joshua C Doloff, David J Waxman
Molecular Cancer|June 27, 2014
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2Joshua C Doloff, Chong-Sheng Chen, David J Waxman
Neoplasia (New York, N.Y.)|February 25, 2014
Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regressionChong-Sheng Chen, Joshua C Doloff, David J Waxman
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Nature Biomedical Engineering|December 13, 2021
Less fibrosis around softer silicone implantsStuart J Bauer, Joshua C Doloff
Nature Materials|March 27, 2021
MAP-ing a way towards tissue repairJessica L Stelzel, Joshua C Doloff
Cancer Research|January 13, 2012
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regressionJoshua C Doloff, David J Waxman
Anti-Cancer Agents in Medicinal Chemistry|July 23, 2013
Adenoviral vectors for prodrug activation-based gene therapy for cancerJoshua C Doloff, David J Waxman
BMC Cancer|May 9, 2015
Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenograftsJoshua C Doloff, David J Waxman
BMC Cancer|September 15, 2010
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+Joshua C Doloff, Ting Su, David J Waxman
Human Gene Therapy|September 6, 2008
Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletionsJoshua C Doloff, David J Waxman, Youssef Jounaidi
Current Cancer Drug Targets|May 17, 2007
Conditionally replicating adenoviruses for cancer treatmentYoussef Jounaidi, Joshua C Doloff, David J Waxman
Molecular Cancer|June 27, 2014
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2Joshua C Doloff, Chong-Sheng Chen, David J Waxman
Neoplasia (New York, N.Y.)|February 25, 2014
Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regressionChong-Sheng Chen, Joshua C Doloff, David J Waxman
Pageof 7